Chronic wounds pose a substantial economic burden on healthcare systems and severely impact the quality-of-life for those affected. “The treatment of chronic wounds is a huge unmet need. This is affecting 1 to 2% of the population,” said Dr Marta Bertolini (QIMA Monasterium GmbH, Germany) [1].
To explore possible innovative wound treatments, Dr Bertolini and colleagues conducted a study using healthy full-thickness human skin according to the punch-in-a-punch wound healing ex-vivo wound model. These samples were then cultured under either physiological or pathological conditions, including hyperglycaemia, oxidative stress, and hypoxia, to mimic acute and chronic wounds, respectively. Using advanced comparative transcriptomic profiling with bulk RNA sequencing, the team monitored gene expression changes over 5 days.
The results showed several critical differences in gene activity between acute and chronic wounds. Key wound repair-associated genes including KRT6A-C, PTX3, KRT1, KRT10, and COL1A1, and pathways such as Wnt signalling and actin cytoskeleton organisation were differentially regulated between acute and chronic wounds. Moreover, overall gene expression was downregulated in chronic wounds compared with acute wounds, which suggests that essential genes required for effective wound healing are inadequately transcribed in these conditions.
Further, fibroblast growth factor 7 (FGF7), a key promoter of epithelial cell proliferation and tissue repair was significantly downregulated in chronic wounds by day 5. Whereas, the tissue-degrading enzyme matrix metalloproteinase-10 (MMP10) was elevated throughout the study period in chronic wounds.
Topical administration of an MMP10-neutralising antibody (alpha-MMP10) in this wound model improved healing in acute wounds. When this antibody was applied together with FGF7, epithelisation in both acute and chronic wounds was enhanced significantly.
“While we must be cautious when discussing synergistic effects, our preliminary data reveal that combinatorial therapy may be a valid option for treating chronic wounds,” explained Dr Bertolini. “We believe that administering excessive FGF7 promotes epidermal keratinocyte proliferation and mobilisation, which are crucial for wound healing. At the same time, neutralising MMP10 removes a barrier to keratinocyte movement, potentially accelerating re-epithelisation,” she concluded.
- Bertolini M. Using comparative transcriptomic profiling ex vivo to identify novel, potential targets for acute and chronic wound healing. FC04.09, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support provided by Dr Susanne Kammerer
Posted on
Previous Article
« Meet the Trialist: Prof. Fred Saad shares insights from the ARANOTE trial Next Article
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence »
« Meet the Trialist: Prof. Fred Saad shares insights from the ARANOTE trial Next Article
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
July 17, 2024
The unfavourable role of obesity in psoriatic disease
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com